A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.

Autor: Eskens, F A L M¹, Tresca, P², Tosi, D², Van Doorn, L¹, Fontaine, H³, Van der Gaast, A¹, Veyrat-Follet, C⁴, Oprea, C³, Hospitel, M⁵, Dieras, V²

Publikováno v: British Journal of Cancer. 4/29/2014, Vol. 110 Issue 9, p2170-2177. 8p.

Differentiation and Definition of Vascular-Targeted Therapies

Autor: Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens, F. A. L. M., Michael Horsman, Marmé, D., Lorusso, P. M.

Publikováno v: Scopus-Elsevier
Siemann, D W, Bibby, M C, Dark, G G, Dicker, A P, Eskens, F A L M, Horsman, M R, Marmé, D & LoRusso, P M 2005, ' Differentiation and definition of vascular-targeted therapies ', Clinical Cancer Research, vol. 11, no. 2 Pt 1, pp. 416-420 . < http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15701823&query_hl=53&itool=pubmed_docsum >
Clinical Cancer Research, 11, 416-420. American Association for Cancer Research Inc.

The therapeutic potential of targeting the tumor vascular supply is now widely recognized. Intense research and development activity has resulted in a variety of investigational agents, a number of which are currently in clinical development. As thes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fef411d0252696c3e487e92ae9bd8475
https://doi.org/10.1158/1078-0432.416.11.2

First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.

Autor: van Meerten, E.¹, Eskens, F. A .L M.¹, van Gameren, E. C.¹, Doorn, L.¹, van der Gaast, A.¹ a.vandergaast@erasmusmc.nl

Publikováno v: British Journal of Cancer. 5/7/2007, Vol. 96 Issue 9, p1348-1352. 5p. 1 Diagram, 1 Chart, 1 Graph.

Hepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and therapy

Autor: Eskens, F. A. L. M., Erpecum, K. J., Jong, K. P., Delden, O. M., Klumpen, H. J., Verhoef, C., Jansen, P. L. M., Den Bosch, M. A. A. J., Méndez Romero, A., Verheij, J., Elisabeth Bloemena, Man, R. A.

Publikováno v: Netherlands Journal of Medicine, 72(6), 299-304. Van Zuiden Communications BV
Scopus-Elsevier
Eskens, F A L M, van Erpecum, K J, de Jong, K P, van Delden, O M, Klumpen, H J, Verhoef, C, Jansen, P L M, van den Bosch, M A A J, Romero, A M, Verheij, J, Bloemena, E & de Man, R A 2014, ' Hepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and therapy ', Netherlands Journal of Medicine, vol. 72, no. 6, pp. 299-304 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f1b1a23120a320e4faac7b4e677b3d15
https://research.vumc.nl/en/publications/7755dbaa-e78e-4ed2-ba6d-b489253fab07

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.